Rss/rsscompary_11212.aspxprbd.net - Submit Press Release and get wide media coverageCopyright 2011 prbdhttps://www.prbd.net/news_47817.aspxA new study expects a robust growth in the future demand of rare earth based magnets. A supply shortage of essential raw materials, however, may endanger the growth of this entire industry.Tue, 17 Apr 2012 00:00:00 GMThttps://www.prbd.net/news_45393.aspxDriven by a large diabetes population, improving healthcare infrastructure and a bright outlook for patented drugs; the diabetes market in India is expected to grow exponentially in the coming years.Tue, 20 Mar 2012 00:00:00 GMThttps://www.prbd.net/news_44893.aspxThe study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market.Thu, 15 Mar 2012 00:00:00 GMThttps://www.prbd.net/news_44592.aspxDriven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years. Mon, 12 Mar 2012 00:00:00 GMThttps://www.prbd.net/news_43830.aspxImplementation of a smart card project requires a significant investment in setting up and upgradation of the current infrastructure. The cost of implementing a smart card based system is very high compared to the cost of smart cards. Fri, 02 Mar 2012 00:00:00 GMThttps://www.prbd.net/news_41738.aspxFindings from the report suggest that the total global spending on clinical is expected to grow at around 4% and that on biopharmaceutical products to grow robustly at 9%.Wed, 08 Feb 2012 00:00:00 GMThttps://www.prbd.net/news_41540.aspxDriven by factors such as increasing popularity in preliminary testing, portability and ease of use; the market for Immunodiagnostics is expected to grow robustly in the coming years. Mon, 06 Feb 2012 00:00:00 GMThttps://www.prbd.net/news_40649.aspxLantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.Wed, 25 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_40543.aspxBiosimilar manufacturers are currently free to copy and manufacture most of the globally marketed therapeutic monoclonal antibodies in India.Tue, 24 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_39982.aspxDriven by a strong demand from both the retail and the institutional sectors, the demand of paneer in India is expected to grow strongly in the coming years. Tue, 17 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_39882.aspxA new report from IMARC Group finds that the Indian market for both diagnostic and therapeutic antibodies is expected to grow exponentially in the coming years.Mon, 16 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_39661.aspxThe volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providersThu, 12 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_39085.aspxA new study from IMARC Group expects the total shipment volume of smart cards in E-Governance projects to reach 372 Million by 2016. Thu, 05 Jan 2012 00:00:00 GMThttps://www.prbd.net/news_38673.aspxThe Modernization of the transportation system in India is expected to create a huge demand of smart cards across the country.Thu, 29 Dec 2011 00:00:00 GMThttps://www.prbd.net/news_38409.aspxAttractive features and subsidies from the RBI have rapidly increased the uptake of EMV cards in recent months.Sat, 24 Dec 2011 00:00:00 GMThttps://www.prbd.net/news_38268.aspxHybrid vehicles largely depend upon four rare earth elements – Praseodymium, Neodymium, Terbium, and Dysprosium. Out of these four elements, the later three are expected to face a critical supply crunch in the near future.Fri, 23 Dec 2011 00:00:00 GMThttps://www.prbd.net/news_36526.aspxTill recently, the telecom sector has been the only prominent user of smart cards in the country. The picture is now undergoing a radical change. Thu, 01 Dec 2011 00:00:00 GMThttps://www.prbd.net/news_36293.aspxExcluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020. Tue, 29 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_36147.aspxA New Report from IMARC Group expects the growth of the biosimilar market to expand the demand of cold chain logistic services in the coming years. Mon, 28 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_35367.aspxBiosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).Thu, 17 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_34935.aspxWith billions of dollars at stake, Pfizer is doing its every bit to save Lipitor from a complete free-fall resulting from its patent expiry later this month. Fri, 11 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_34396.aspxWith demand expected to significantly outpace supply in the coming years, India may not have enough milk to feed its own population - let alone feed others. Sat, 05 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_34018.aspxWith the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers. Wed, 02 Nov 2011 00:00:00 GMThttps://www.prbd.net/news_33519.aspxDespite a recent bust, prospects for rare earth stocks will remain strong in the long term. Investors, however, will have to closely analyze the grade and composition of individual rare earths before investing in a mine.Tue, 25 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_33399.aspxWith sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint.Tue, 25 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_32250.aspxA new report from IMARC Group expects Amgen to lose brand sales worth US$ 8.4 Billion during 2010 and 2020 mainly as a result of biosimilar erosion.Tue, 11 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_32112.aspxA new report from IMARC Group finds that one of the biggest advantages of biopharmaceuticals over conventional small molecule drugs is their high efficacy and target oriented nature.Mon, 10 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_32044.aspx A new report from IMARC Group suggests that an increased research and development into technologies that nullify the need of cold chains could restrain the growth of the global cold chain logistics industry. Sun, 09 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_31699.aspxDespite worldwide efforts to reduce the consumption of rare earth elements, IMARC Group expects strategies like substitution and recycling to have a little effect on their demand and dependability in the short termTue, 04 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_31598.aspxA new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors to drive sales in the Canadian Oral Antidiabetics market during 2011-2016Mon, 03 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_31523.aspxA new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors and other new drug classes to drive sales in the Turkish Oral Antidiabetics market during 2011-2016Sat, 01 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_31502.aspxA new report from IMARC Group expects new drug launches to drive the growth of the Japanese Oral Antidiabetics market during 2011-2016Sat, 01 Oct 2011 00:00:00 GMThttps://www.prbd.net/news_31121.aspxA new report from IMARC Group expects several factors such as value addition, increasing penetration in the cold beverage segment and rising institutional sales to drive the Indian tea market to sales worth US$ 7.2 Billion by 2016.Tue, 27 Sep 2011 00:00:00 GMThttps://www.prbd.net/news_30632.aspxHealthcare manufacturers today are becoming more and more receptive to the notion that rather than risking the wastage of such high value products, it is more preferable to pay the extra cash to strengthen their distribution systems.Thu, 22 Sep 2011 00:00:00 GMThttps://www.prbd.net/news_30380.aspxWith its demand significantly outpacing supply, Neodymium is expected to face a critical supply shortage in the coming years.Tue, 20 Sep 2011 00:00:00 GMThttps://www.prbd.net/news_29042.aspxA new report from IMARC Group expects the future growth of the NiMH battery market to be significantly impacted by a supply shortage of NeodymiumFri, 02 Sep 2011 00:00:00 GMThttps://www.prbd.net/news_29036.aspxA new report from IMARC Group expects the strong growth of biopharmaceuticals and the launch of biosimilars to create huge opportunities for cold chain service providersFri, 02 Sep 2011 00:00:00 GMThttps://www.prbd.net/news_28082.aspxA new study from IMARC Group suggests that it will take around 4 to 5 years for the country’s skimmed milk powder production to reach levels that it had in 2008-09.Thu, 18 Aug 2011 00:00:00 GMThttps://www.prbd.net/news_27770.aspxA new report from IMARC Group expects the future growth of the energy efficient lighting and modern display industries to be constrained by a critical supply shortage of Terbium and Europium.Thu, 11 Aug 2011 00:00:00 GMThttps://www.prbd.net/news_27648.aspxDriven by an increasing prevalence of diabetes, the total market for Insulin and Non-Insulin Antidiabetics is expected to reach sales worth US$ 2803 Million by 2015.Wed, 10 Aug 2011 00:00:00 GMThttps://www.prbd.net/news_27396.aspxWith outsourcing trends in the global clinical trials market increasing rapidly, the demand of efficient cold chain logistic services is predicted to grow robustly in the coming years.Sat, 06 Aug 2011 00:00:00 GMThttps://www.prbd.net/news_27392.aspxA new report from IMARC Group expects that as a result of an avalanche of patent expiries and a thin pipeline, sales worth US$ 8.7 Billion will be eroded from the US cholesterol lowering agent market.Sat, 06 Aug 2011 00:00:00 GMThttps://www.prbd.net/news_26672.aspxA new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.Wed, 27 Jul 2011 00:00:00 GMThttps://www.prbd.net/news_26577.aspxDriven by a high shelf life and an increased convenience, the demand for UHT milk in India is expected to grow more than three folds during 2010-11 and 2016-17.Tue, 26 Jul 2011 00:00:00 GMThttps://www.prbd.net/news_25932.aspxA new report from IMARC Group expects an exponential growth in the demand of rare earth based magnets in the coming years. A supply shortage of key raw materials, however, may jeopardize the growth of this entire industry.Mon, 18 Jul 2011 00:00:00 GMThttps://www.prbd.net/news_25061.aspxFrom less than 3% in 2010, Non-Chinese mines are expected to account for more than 37% of the global rare earth elements production by 2015, says a new report from IMARC GroupMon, 04 Jul 2011 00:00:00 GMT